IDH2 and acute myeloid leukemia: The phase 1/2 NCT06445959 and NCT04603001 studies are investigating novel-generation IDH-inhibitors for R/R IDH-mutated AML not eligible for IC, such as olutasidenib or the dual IDH1- and IDH2-inhibitor crelosidenib.